UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants

Pediatric pulmonology, 2018-05, Vol.53 (5), p.605-612

2018

Volltextzugriff (PDF)

Interaction between healthcare professionals and parents is a key determinant of parental distress during childhood hospitalisation for respiratory syncytial virus infection (European RSV Outcomes Study [EROS])

Acta Paediatrica, 2018-05, Vol.107 (5), p.854-860

2018

Volltextzugriff (PDF)

IBD2020 global forum: results of an international patient survey on quality of care

Intestinal research, 2018, 16(4), , pp.537-545

2018

Volltextzugriff (PDF)

Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries

Expert review of anti-infective therapy, 2021-04, Vol.19 (4), p.419-441

2021

Volltextzugriff (PDF)

Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants

Current medical research and opinion, 2021-07, Vol.37 (7), p.1-1153

2021

Volltextzugriff (PDF)

Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants

Journal of medical economics, 2023-12, Vol.26 (1), p.630-643

2023

Volltextzugriff (PDF)

Introduction of biosimilar pegfilgrastim in France: Economic analysis of switching from originator

Journal of oncology pharmacy practice, 2021-10, Vol.27 (7), p.1604-1615

2021

Volltextzugriff (PDF)

Pulse oximetry screening for critical congenital heart defects: a European consensus statement

The lancet child & adolescent health, 2017-10, Vol.1 (2), p.88-90

2017

Volltextzugriff (PDF)

Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries

Frontiers in pediatrics, 2022-11, Vol.10, p.1033125-1033125

2022

Volltextzugriff (PDF)

Can we improve the targeting of respiratory syncytial virus (RSV) prophylaxis in infants born 32-35 weeks' gestational age with more informed use of risk factors?

The journal of maternal-fetal & neonatal medicine, 2015-07, Vol.28 (10), p.1133-1141

2015

Volltextzugriff (PDF)

The influence of birth weight amongst 33-35 weeks gestational age (wGA) infants on the risk of respiratory syncytial virus (RSV) hospitalisation: a pooled analysis

The journal of maternal-fetal & neonatal medicine, 2017-01, Vol.30 (2), p.134-140

2017

Volltextzugriff (PDF)

Prioritising respiratory syncytial virus prevention in low-income and middle-income countries

The Lancet global health, 2023-05, Vol.11 (5), p.e655-e657

2023

Volltextzugriff (PDF)

Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants

Current Medical Research and Opinion, 2021, Vol.37 (7), p.1149-1153

2021

Volltextzugriff (PDF)

Association between respiratory syncytial virus hospitalization in infancy and childhood asthma

Pediatric pulmonology, 2020-05, Vol.55 (5), p.1104-1110

2020

Volltextzugriff (PDF)

Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants

Frontiers in pediatrics, 2024, Vol.12, p.1343960-1343960

2024

Volltextzugriff (PDF)

Perspective: the potential of wastewater-based surveillance as an economically feasible game changer in reducing the global burden of pediatric respiratory syncytial virus infection

Frontiers in public health, 2023, Vol.11, p.1316531-1316531

2023

Volltextzugriff (PDF)

Infliximab use in Crohnʼs disease: impact on health care resources in the UK

European journal of gastroenterology & hepatology, 2005-10, Vol.17 (10), p.1047-1052

2005

Volltextzugriff (PDF)

Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants

The Journal of infectious diseases, 2023-05, Vol.227 (11), p.1333-1334

2023

Volltextzugriff (PDF)

50 New Analysis on the Cost-effectiveness of Palivizumab (PVZ) for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Canadian Infants Born 29-31 and 32-35 weeks’ Gestational Age (wGA)

Paediatrics & child health, 2023-09, Vol.28 (Supplement_1), p.e22-e22

2023

Volltextzugriff (PDF)

Clinical burden of severe respiratory syncytial virus infection during the first 2 years of life in children born between 2000 and 2011 in Scotland

European journal of pediatrics, 2020-05, Vol.179 (5), p.791-799

2020

Volltextzugriff (PDF)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

Gut, 2012-04, Vol.61 (4), p.535-542

2012

Volltextzugriff (PDF)

A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age

PloS one, 2023-08, Vol.18 (8), p.e0289828-e0289828

2023

Volltextzugriff (PDF)

Burden of Severe Respiratory Syncytial Virus Disease Among 33–35 Weeks’ Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons

The Pediatric infectious disease journal, 2017-02, Vol.36 (2), p.160-167

2017

Volltextzugriff (PDF)

Infliximab use in Crohn??s disease: impact on health care resources in the UK

European journal of gastroenterology & hepatology, 2005-10, Vol.17 (10), p.1047-1052

2005

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(23)
Berichte
(1)

Sprache

Englisch
(24)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(21)
Life Sciences & Biomedicine
(20)
Respiratory Syncytial Virus
(13)
Humans
(11)
Infant
(8)
Pediatrics
(8)
Risk Factors
(8)
Bronchiolitis
(7)
Hospitalization
(6)
Infant, Newborn
(6)
Lower Respiratory Tract Infection
(6)
Gestational Age
(5)
Infant, Premature
(5)
Risk Assessment
(5)
Female
(4)
Male
(4)
Original
(4)
Prematurity
(4)
Prophylaxis
(4)
Respiratory Syncytial Virus Infections - Epidemiology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants

Interaction between healthcare professionals and parents is a key determinant of parental distress during childhood hospitalisation for respiratory syncytial virus infection (European RSV Outcomes Study [EROS])

IBD2020 global forum: results of an international patient survey on quality of care

Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries

Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants

Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants

Introduction of biosimilar pegfilgrastim in France: Economic analysis of switching from originator

Pulse oximetry screening for critical congenital heart defects: a European consensus statement

Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries

Can we improve the targeting of respiratory syncytial virus (RSV) prophylaxis in infants born 32-35 weeks' gestational age with more informed use of risk factors?

The influence of birth weight amongst 33-35 weeks gestational age (wGA) infants on the risk of respiratory syncytial virus (RSV) hospitalisation: a pooled analysis

Prioritising respiratory syncytial virus prevention in low-income and middle-income countries

Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants

Association between respiratory syncytial virus hospitalization in infancy and childhood asthma

Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants

Perspective: the potential of wastewater-based surveillance as an economically feasible game changer in reducing the global burden of pediatric respiratory syncytial virus infection

Infliximab use in Crohnʼs disease: impact on health care resources in the UK

Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants

50 New Analysis on the Cost-effectiveness of Palivizumab (PVZ) for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Canadian Infants Born 29-31 and 32-35 weeks’ Gestational Age (wGA)

Clinical burden of severe respiratory syncytial virus infection during the first 2 years of life in children born between 2000 and 2011 in Scotland

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age

Burden of Severe Respiratory Syncytial Virus Disease Among 33–35 Weeks’ Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons

Infliximab use in Crohn??s disease: impact on health care resources in the UK

Suchergebnisse filtern